Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.61 |
| ▸ | CA2 | P00918 | 10/20 | 0.61 |
| ▸ | CA9 | Q16790 | 8/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA7 | P43166 | 3/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.61 |
| ▸ | CA3 | P07451 | 2/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | CA6 | P23280 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 2/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octadecyl Sulfate SCHEMBL41459 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL4904743 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| Octadecyl Sulfate SCHEMBL146302 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL2233821 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL374800 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL9018754 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL8076339 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL10583495 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL22283885 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL3353 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058067-A1 | COMPOSITIONS FOR TREATING KERATIN-CONTAINING FIBERS AND MAINTAINING DYED FIBER COLOR INTEGRITY | Kelly Van Gogh, LLC | 2012-03-08 | — | — | US | claimed |
| US-20120058068-A1 | COMPOSITIONS FOR REPAIRING AND RESTORING KERATIN-CONTAINING FIBERS | KELLY VAN GOGH. LLC | 2012-03-08 | — | — | US | disclosed |
| US-20120055840-A1 | COMPOSITIONS FOR DYEING KERATIN-CONTAINING FIBERS | KELLY VAN GOGH, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20120058067-A1 | COMPOSITIONS FOR TREATING KERATIN-CONTAINING FIBERS AND MAINTAINING DYED FIBER COLOR INTEGRITY | Kelly Van Gogh, LLC | 2012-03-08 | — | — | US | disclosed |
| US-8052762-B1 | Compositions for dyeing keratin-containing fibers | Kelly Van Gogh, LLC (US) | 2011-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058068-A1 | COMPOSITIONS FOR REPAIRING AND RESTORING KERATIN-CONTAINING FIBERS | KRT18, COL14A1, COL2A1 | CA1 3888/4885CA2 4597/4885CA9 4187/4885 |
| US-20120055840-A1 | COMPOSITIONS FOR DYEING KERATIN-CONTAINING FIBERS | KRT18, JUP, CKAP4 | CA1 1998/4885CA2 2930/4885CA9 1368/4885 |
| US-20120058067-A1 | COMPOSITIONS FOR TREATING KERATIN-CONTAINING FIBERS AND MAINTAINING DYED FIBER COLOR INTEGRITY | KRT18, COL1A1, COL14A1 | CA1 1827/4885CA2 3147/4885CA9 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.